Open Orphan | Business Post

Irish-founded hVIVO lands €7.5m contract to test vaccines

The trials are aimed at eliminating respiratory diseases which kill thousands of people each year

Hvivo to make return to shareholders from strong 2022 results

Pharmaceutical services company expects full-year revenues of £50.6 million for 2022, a 30 per cent increase year-on-year

Cathal Friel’s Hvivo expects record revenue of £50.6 million in 2022

The Dublin-listed company formerly known as Open Orphan has issued a trading update

The Big Interview

‘Way too many people worry too much about big cars and fancy houses’ – Cathal Friel

Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market

Open Orphan founder says Covid-19 ‘is over’

Cathal Friel, the head of the pharma firm, has contradicted official advice to isolate, and says the virus should now be treated like a cold or flu

Open Orphan swings to profit for the first time after ‘milestone year’ for the firm

Revenue at the pharmaceutical services company increased almost 80 per cent last year after it secured a number of large contracts

Oral vaccines for Covid-19 expected by 2030

Dublin and Cork-based firms are collaborating to bring infectious disease prevention to the ‘next level’

Open Orphan subsidiary signs €6m contract with European biotech company

The Dublin-listed pharmaceutical services company said it expects the contract win will generate revenue across its financial years for 2022 and 2023

Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO

Ambitions are high for Poolbeg Pharma, which will develop drugs to fight infectious diseases

Open Orphan starts trials on nasal spray Covid-19 vaccines

Trials have begun on next-generation vaccine, says Cathal Friel, executive chairman of Irish pharma digital services firm